Status:
RECRUITING
Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial
Lead Sponsor:
Nova Scotia Health Authority
Conditions:
Insomnia
Dementia
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Insomnia is a highly common, chronic disorder that is distressful for the patient but also for caregivers and can give rise to a heavy burden on the healthcare team. Sleeping aids like benzodiazepines...
Detailed Description
Background \& Rationale Insomnia is a highly common, chronic disorder that is distressful for the patient but also for caregivers and can give rise to a heavy burden on the healthcare team. Sleeping a...
Eligibility Criteria
Inclusion
- Identified by clinician investigator to have early-onset dementia and a significant component of insomnia.
Exclusion
- Known sleep disorders that are contraindications for orexin antagonist therapy.
Key Trial Info
Start Date :
December 11 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 11 2028
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT06093126
Start Date
December 11 2023
End Date
December 11 2028
Last Update
February 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nova Scotia Health
Halifax, Nova Scotia, Canada, B3H 2E1